Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics
TRVI Price/Volume Stats
| Current price | $2.78 | 52-week high | $4.00 |
| Prev. close | $2.86 | 52-week low | $1.00 |
| Day low | $2.75 | Volume | 38,912 |
| Day high | $2.86 | Avg. volume | 302,248 |
| 50-day MA | $3.03 | Dividend yield | N/A |
| 200-day MA | $2.93 | Market Cap | 213.69M |
TRVI Stock Price Chart Interactive Chart >
Trevi Therapeutics, Inc. (TRVI) Company Bio
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
TRVI Price Returns
| 1-mo | -7.64% |
| 3-mo | -5.76% |
| 6-mo | 12.55% |
| 1-year | 150.45% |
| 3-year | 209.51% |
| 5-year | -28.72% |
| YTD | 107.46% |
| 2023 | -30.57% |
| 2022 | 146.74% |
| 2021 | -67.68% |
| 2020 | -35.47% |
| 2019 | N/A |
Loading social stream, please wait...